|Bid||203.67 x 1000|
|Ask||205.64 x 1100|
|Day's Range||203.76 - 206.23|
|52 Week Range||200.47 - 276.69|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||16.90|
|Earnings Date||Jan. 31, 2022 - Feb. 04, 2022|
|Forward Dividend & Yield||7.04 (3.37%)|
|Ex-Dividend Date||Aug. 16, 2021|
|1y Target Est||250.00|
Biopharmaceutical stocks are slated to end the year on a sour note. This industrywide sell-off has also picked up momentum during the waning days of Nov., with an eye-popping 358 biopharma stocks falling by more than 10% during just the past three weeks. Savvy investors, though, know that steep drops in the market typically represent compelling buying opportunities.
Amgen beat analysts' earnings expectations in the third quarter, and its balance sheet remains admirable.
Second, dividend stocks have historically outperformed their peers that do not pay dividends. Two companies that would be great additions to your dividend portfolio are pharma giants Bristol Myers Squibb (NYSE: BMY) and Amgen (NASDAQ: AMGN). The company continues to post solid financial results thanks to its rich lineup of drugs.